Roche Holding AG / Sarepta Therapeutics Inc.

Duchenne Muscular Dystrophy (Gene Therapy)

400 US cases/yr · $2.1B North America DMD Treatment (2024)

Disease Overview

Duchenne muscular dystrophy (DMD) is a severe, X-linked recessive neuromuscular disorder caused by out-of-frame mutations in the DMD gene encoding dystrophin, resulting in absent or near-absent functional dystrophin at the muscle sarcolemma. It is the most common childhood muscular dystrophy, with an estimated incidence of approximately 1 in 3,500-5,000 live male births. Boys typically present between ages 2 and 5 with delayed motor milestones, toe walking, calf pseudohypertrophy, proximal muscle weakness, and a positive Gowers sign; most lose independent ambulation by the early teens. Progressive involvement of cardiac and respiratory muscles leads to dilated cardiomyopathy and restrictive lung disease, which are the principal causes of death, historically in the second to third decade. Diagnosis combines markedly elevated serum creatine kinase with genetic testing of the DMD gene; muscle biopsy with dystrophin immunostaining is used when genetic testing is non-diagnostic. Standard-of-care management includes corticosteroids (prednisone or deflazacort, vamorolone), physical and occupational therapy, cardiac surveillance with early initiation of ACE inhibitors/ARBs and beta-blockers, and proactive respiratory support (non-invasive ventilation, cough assist). Disease-modifying therapies now include exon-skipping antisense oligonucleotides for amenable mutations and AAV-delivered micro-dystrophin gene therapy.

Commercial Performance

Elevidys achieved blockbuster status rapidly at $3.2M per patient. Roche holds ex-US rights. Challenges: confirmatory EMBARK trial showed mixed results (primary endpoint missed but functional secondary endpoints improved), manufacturing complexity (AAV production), and limited eligible population. The accelerated approval pathway allows early revenue while confirmatory data matures.

Limb-Girdle Muscular Dystrophy Type 2E/R4

Competitive Landscape

SRP-9003 (bidridistrogene xeboparvovec) is a Sarepta AAVrh74-delivered gene therapy encoding beta-sarcoglycan for LGMD2E/R4, which met its primary endpoint in the Phase 3 EMERGENE trial and is under FDA review with a BLA filed. The commercial landscape is defined almost entirely by MOA class context rather than direct indication competitors, because LGMD2E has no approved disease-modifying therapy. Direct competition groups by MOA class: AAV micro-dystrophin/sarcoglycan gene therapies, antisense oligonucleotide exon-skipping, CRISPR-based gene editing, and supportive care/steroids. In the AAV gene therapy class, Sarepta's own Elevidys (delandistrogene moxeparvovec, FDA-approved 2023 for DMD ambulatory 4-5y, expanded 2024, first AAV muscle gene therapy) is the commercial anchor and validates Sarepta's AAVrh74 platform. Other AAV LGMD programs include Sarepta's SRP-9004 (LGMD2D/alpha-sarcoglycan), SRP-9005 (LGMD2C/gamma-sarcoglycan), and Atamyo Therapeutics' ATA-100 (LGMD2I/R9, fukutin-related protein, Phase 1/2). In the exon-skipping ASO class, Sarepta's Exondys 51 (eteplirsen), Vyondys 53 (golodirsen), and Amondys 45 (casimersen) are DMD-only, not LGMD. In CRISPR/editing, Vertex and Editas programs remain preclinical for muscular dystrophies. Supportive care: prednisone, deflazacort (Emflaza, PTC). Commercial takeaway: LGMD2E has no approved competitor; SRP-9003 would create the category and faces no direct franchise threat.